
ESOCAP CEO INTERVIEWED BY CCFA

Basel, Switzerland, February 24, 2023

EsoCap CEO interviewed by CCFA as part of International Women's Day.

"I am very pleased to have been selected to give an interview in Caléidoscope, the journal of the CCFA (French-Austrian Chamber of Commerce) as part of International Women's Day," said Isabelle Racamier, CEO of EsoCap AG. "This recognition reinforces our commitment to make EsoCap's promising and unique technology a significant improvement in patients' lives."

About the CCFA

The CCFA (French-Austrian Chamber of Commerce) is part of the international network of CCI France International (Association of French Chambers of Commerce and Industry Abroad) and aims to promote and foster relations and the exchange of information between Austria and France, in particular between business people and entrepreneurs.

The strength of our chamber is a particularly active network in Austria.



About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with severe upper gastrointestinal tract diseases by developing a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve with the current standard of care because the contact time of the drug from the mouth to the stomach is extremely short at one to two seconds.

EsoCap has a unique drug delivery platform that enables local treatment of upper gastrointestinal tract disorders with an unprecedented prolonged contact time with the esophageal mucosa.

For more information, please visit www.esocapbiotech.com and follow EsoCap on [LinkedIn](#) and [Twitter](#).

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com